Flavocure Biotech
Baltimore, US · Founded 2018 · Delaware corporation
Flavocure Biotech is a biotechnology company developing flavonoid-derived compounds from cannabis as therapeutics for cancers such as metastatic pancreatic cancer and other conditions. It conducts preclinical drug research and development.
BiotechHealthtech
Founders & leadership
DL
Douglas LiuExecutive
NT
Ngeh ToyangNamed on SEC filing
HL
Henry LoweNamed on SEC filing
TL
Thomas LanginNamed on SEC filing
DB
David BrooksinNamed on SEC filing
Board
JG
Justin GrantBoard director
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 2 rounds · 2022–2025
▶$215KraisedFeb 2025 · 3 investors · BiotechnologyRule 506(b)
▶$215KraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ngeh ToyangExecutive Officer, Director
- Justin GrantDirector
- Henry LoweExecutive Officer, Director
- Douglas LiuExecutive Officer
- Offering amount
- $2M
- Amount sold
- $215K
- Minimum investment
- $25K
- Proceeds to insiders
- $250K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJan 2023 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJan 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Swen SimmsPromoter
- Eric ChapmanPromoter
- Ngeh ToyangExecutive Officer, Director
- Henry LoweExecutive Officer, Director
- Douglas LiuExecutive Officer
- David TraylorPromoter
- Justin GrantDirector
- Theresia ToyengPromoter
- Thomas LangExecutive Officer
- David BrooksExecutive Officer
- Anthony DeaseyPromoter
- Saurabh SewakPromoter
- Offering amount
- $1.3M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- Proceeds to insiders
- $168.9K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
NovoCure15 shared keywordsNovocure is a global oncology company developing Tumor Treating Fields therapies, including its Optune Pax device, to treat aggressive cancers such as locally advanced pancreatic cancer. It serves cancer patients and their treating physicians in the medical device and healthcare sector.
Onkure Therapeutics Inc14 shared keywordsOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Capricor9 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Flavocure Biotech for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Flavocure Biotech do?
- Flavocure Biotech is a biotechnology company developing flavonoid-derived compounds from cannabis as therapeutics for cancers such as metastatic pancreatic cancer and other conditions. It conducts preclinical drug research and development.
- How much funding has Flavocure Biotech raised?
- Flavocure Biotech has disclosed $1.3M raised across 2 rounds.
- Where is Flavocure Biotech headquartered?
- Flavocure Biotech is headquartered in Baltimore, US.